A Comparative Efficacy Trial in Germany in Infants Who Received Either the Lederle/Takeda Acellular Pertussis Component DTP (DTaP) Vaccine, the Lederle Whole-Cell Component DTP Vaccine, or DT Vaccine
- 1 January 1998
- journal article
- clinical trial
- Published by American Academy of Pediatrics (AAP) in PEDIATRICS
- Vol. 101 (1), 1-11
- https://doi.org/10.1542/peds.101.1.1
Abstract
Background. The goal of the trial was to determine the efficacy of a multicomponent acellular pertussis vaccine against Bordetella illnesses in comparison with a whole-cell product and DT. Design. In a randomized, double-blind fashion, 2- to 4-month-old infants received 4 doses of either DTP or DTaP vaccine at 3, 4.5, 6, and 15 to 18 months of age. The controls received 3 doses (3, 4.5, 15 to 18 months of age) of DT vaccine. The DTP vaccine was Lederle adsorbed vaccine (licensed in the United States) and DTaP was Lederle/Takeda adsorbed vaccine. Follow-up for vaccine efficacy started 2 weeks after the third dose (DTP/DTaP) and at the same age (6.5 months) in DT recipients. Reactogenicity of all doses of all three vaccines was documented by standardized parent diary cards. In addition, all subjects were monitored for respiratory illnesses and serious adverse events by biweekly phone calls. Results. From May 1991 to January 1993, a total of 10 271 infants were enrolled: 8532 received either DTP or DTaP and 1739 received DT. Specific efficacy against B pertussisinfections with cough ≥7 days duration was 83% (95% confidence interval [CI]: 76–88) and 72% (95% CI: 62–79) for DTP and DTaP, respectively; results for DTP and DTaP based on ≥21 days of cough with either paroxysms, whoop or posttussive vomiting (PWV) were 93% (95% CI: 89–96) and 83% (95% CI: 76–88), respectively. For DTaP vaccine, efficacy was higher after the fourth dose as compared with its efficacy after the third dose (78% vs 62% for cough ≥7 days and 85% vs 76% for cough ≥21 days with PWV). For DTP vaccine, efficacy was less varied after the third and fourth dose (78% vs 85% for cough ≥7 days and 93% vs 93% for cough ≥21 days with PWV). In contrast with DTP, the DTaP vaccine had some efficacy against B parapertussisinfection (point estimate for cough ≥7 days: 31% [95% CI: −10–56]). All vaccines were generally well-tolerated. However, side reactions were significantly less after DTaP compared with DTP. Conclusions. Like other multicomponent acellular pertussis vaccines, the Lederle/Takeda DTaP vaccine demonstrated good efficacy against mild and typical pertussis due to B pertussisinfections. Interestingly, it also may have some efficacy againstB parapertussis. Based on the results of this trial, the vaccine was licensed in the United States in December 1996 for all 5 doses of the currently recommended immunization schedule in this country.Keywords
This publication has 28 references indexed in Scilit:
- Unchanged efficacy of a pertussis toxoid vaccine throughout the two years after the third vaccination of infantsThe Pediatric Infectious Disease Journal, 1997
- Polymerase chain reaction identification of Bordetella pertussis infections in vaccinees and family members in a pertussis vaccine efficacy trial in GermanyThe Pediatric Infectious Disease Journal, 1995
- Clinical characteristics of illness caused by Bordetella parapertussis compared with illness caused by Bordetella pertussisThe Pediatric Infectious Disease Journal, 1994
- Clinical and laboratory diagnosis of pertussis in the regions of a large vaccine efficacy trial in GermanyThe Pediatric Infectious Disease Journal, 1993
- Reactogenicity and immunogenicity of a double-strength acellular pertussis vaccineVaccine, 1992
- Safety and immunogenicity of acellular pertussis vaccine, combined with diphtheria and tetanus as the Japanese commercial Takeda vaccine, compared with the Takeda acellular pertussis component combined with Lederleʼs diphtheria and tetanus toxoids in two-, four- and six-month-old infantsThe Pediatric Infectious Disease Journal, 1992
- Comparison of acellular and whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infantsThe Journal of Pediatrics, 1991
- Comparison of an acellular pertussis-component diphtheria-tetanus-pertussis (DTP) vaccine with a whole-cell pertussis-component DTP vaccine in 17- to 24-month-old children, with measurement of 69-kilodalton outer membrane protein antibodyThe Journal of Pediatrics, 1990
- Differences in Reactogenicity and Antigenicity of Acellular and Standard Pertussis Vaccines Combined with Diphtheria and Tetanus in InfantsThe Journal of Infectious Diseases, 1988
- OBSERVATIONS ON PARAPERTUSSIS IN DENMARK, 1950–1957Acta Pathologica Microbiologica Scandinavica, 1958